2169232-81-7
2169232-81-7
Chemical Structure
Magrolimab
Synonym(s): Hu5F9-G4
- CAS No.: 2169232-81-7
- Formula:N/A
- Molecular Weight:(145.73 kDa)
IUPAC Name: 2-(ethoxy-d5)-3,3-dimethyl-2,3-dihydrobenzofuran-5-yl methanesulfonate
SMILES: [Magrolimab]
Biological Activity: Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Magrolimab | 99.92% | Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab, an IgG4 isotype, lacks ADCC function and exhibits relatively weak ADCP effector function. Magrolimab can be used for the study of malignant bone tumors and breast cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. [Content Brief]
- [2]. Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. [Content Brief]
- [3]. Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. [Content Brief]
Keywords
